Alevatrix is an injectable long-acting formulation of the local anesthetic, bupivacaine, under development to enable opioid-free management of postoperative pain. The product is based on Rebel Medicine’s proprietary Lipitrix injectable gel technology and will be packaged in a ready-to-use, prefilled syringe that can be used in both regional anesthesia via nerve blocks and local anesthesia via instillation. 

​

Opioid-based medications are a mainstay of postoperative pain management today with approximately 80% of surgical patients receiving opioid prescriptions after surgery. However, their use is associated with a variety of adverse events, prolonged hospital length of stay and increased costs of care. The pain after surgery is most intense in the first 72 hours, after which non-opioid systemic medications such as acetaminophen and NSAIDs are sufficient for most patients. Alevatrix has demonstrated in large animal models that it can control pain locally through the first 72-96 hours. By minimizing or eliminating the need for opioids after surgery, Alevatrix has the potential to reduce the cost and improve outcomes for patients undergoing surgery.

​

Rebel Medicine has performed extensive preclinical evaluations of Alevatrix in validated and translatable large animal models and is targeting 72-96 hours of pain relief after a single administration. IND-enabling studies were initiated in Q1 2023 and Rebel Medicine expects to submit for IND opening by EOY 2023.